Mackay Shields LLC acquired a new stake in Becton Dickinson and Co (NYSE:BDX) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 49,371 shares of the medical instruments supplier’s stock, valued at approximately $11,124,000.
A number of other institutional investors have also recently made changes to their positions in BDX. PRW Wealth Management LLC acquired a new position in Becton Dickinson and in the fourth quarter valued at approximately $69,000. SevenBridge Financial Group LLC boosted its stake in Becton Dickinson and by 6.0% in the fourth quarter. SevenBridge Financial Group LLC now owns 13,398 shares of the medical instruments supplier’s stock valued at $3,019,000 after acquiring an additional 762 shares during the period. Financial Advisors LLC acquired a new position in Becton Dickinson and in the fourth quarter valued at approximately $578,000. Nomura Holdings Inc. boosted its stake in Becton Dickinson and by 8.8% in the fourth quarter. Nomura Holdings Inc. now owns 5,882 shares of the medical instruments supplier’s stock valued at $1,323,000 after acquiring an additional 475 shares during the period. Finally, Kings Point Capital Management boosted its stake in Becton Dickinson and by 1.5% in the fourth quarter. Kings Point Capital Management now owns 31,164 shares of the medical instruments supplier’s stock valued at $7,022,000 after acquiring an additional 462 shares during the period. 85.46% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages have commented on BDX. TheStreet upgraded Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. Zacks Investment Research downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Wednesday, February 6th. Morgan Stanley decreased their target price on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 2nd. Deutsche Bank began coverage on Becton Dickinson and in a research note on Thursday, December 6th. They issued a “buy” rating and a $280.00 target price for the company. Finally, UBS Group started coverage on Becton Dickinson and in a research note on Tuesday, November 27th. They issued a “neutral” rating and a $260.00 target price for the company. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Becton Dickinson and has a consensus rating of “Buy” and a consensus target price of $253.55.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.58 by $0.12. The business had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The business’s revenue was up 35.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.48 earnings per share. On average, analysts predict that Becton Dickinson and Co will post 12.1 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be given a dividend of $0.77 per share. The ex-dividend date is Thursday, March 7th. This represents a $3.08 annualized dividend and a dividend yield of 1.21%. Becton Dickinson and’s dividend payout ratio is presently 27.97%.
In other news, CEO Vincent A. Forlenza sold 11,340 shares of the business’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $250.40, for a total transaction of $2,839,536.00. Following the completion of the transaction, the chief executive officer now directly owns 227,250 shares in the company, valued at $56,903,400. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Ribo Alberto Mas sold 4,808 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $255.03, for a total value of $1,226,184.24. Following the transaction, the executive vice president now owns 22,476 shares of the company’s stock, valued at $5,732,054.28. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 19,271 shares of company stock valued at $4,862,179. Insiders own 0.12% of the company’s stock.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: Investing strategies using the yield curve
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.